{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:00:29Z","timestamp":1779886829974,"version":"3.53.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.yebeh.2019.02.020","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T07:00:59Z","timestamp":1552719659000},"page":"59-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan"],"prefix":"10.1016","volume":"94","author":[{"given":"Vibeke","family":"Arntsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strandheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid B.","family":"Helland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylert","family":"Brodtkorb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S2","key":"10.1016\/j.yebeh.2019.02.020_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/epd.2016.0844","article-title":"Neuronal ceroid lipofuscinoses","volume":"18","author":"Nita","year":"2016","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2019.02.020_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2007-973654","article-title":"Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures","volume":"28","author":"Uvebrant","year":"1997","journal-title":"Neuropediatrics"},{"issue":"11","key":"10.1016\/j.yebeh.2019.02.020_bb0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/08830738060210110801","article-title":"Occurrence of and mortality from childhood neuronal ceroid lipofuscinoses in Norway","volume":"21","author":"Augestad","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2019.02.020_bb0020","first-page":"347","article-title":"Beretning om et m\u00e6rkeligt sygdomstilf\u00e6lde hos fire s\u00f8dskende i n\u00e6rheden af R\u00f8raas","volume":"1","author":"Stengel","year":"1826","journal-title":"Eyr"},{"issue":"10","key":"10.1016\/j.yebeh.2019.02.020_bb0025","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1528-1157.2000.tb04608.x","article-title":"Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis","volume":"41","author":"\u00c5berg","year":"2000","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2019.02.020_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1212\/WNL.0000000000000077","article-title":"Progressive myoclonic epilepsies: definitive and still undetermined causes","volume":"82","author":"Franceschetti","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.yebeh.2019.02.020_bb0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000000091","article-title":"Progressive myoclonic epilepsies: it takes a village to make a diagnosis","volume":"82","author":"Knupp","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2019.02.020_bb0040","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dmcn.12634","article-title":"Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis","volume":"57","author":"Augustine","year":"2015","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl. A","key":"10.1016\/j.yebeh.2019.02.020_bb0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ejpn.2000.0465","article-title":"Cardiac pathology in neuronal ceroid lipofuscinoses\u2013a clinicopathologic correlation in three patients","volume":"5","author":"Hofman","year":"2001","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2019.02.020_bb0050","first-page":"357","article-title":"Cardiac involvement in juvenile amaurotic idiocy\u2013a specific heart muscle disorder. Histological findings in 13 autopsied patients","volume":"89","author":"Reske-Nielsen","year":"1981","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"10.1016\/j.yebeh.2019.02.020_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autneu.2018.07.003","article-title":"Paroxysmal sympathetic hyperactivity in juvenile neuronal ceroid lipofuscinosis (Batten disease)","volume":"214","author":"Ostergaard","year":"2018","journal-title":"Auton Neurosci"},{"issue":"4","key":"10.1016\/j.yebeh.2019.02.020_bb0060","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2019.02.020_bb0065","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.clinph.2017.07.418","article-title":"Standardized computer-based organized reporting of EEG: SCORE - second version","volume":"128","author":"Beniczky","year":"2017","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2019.02.020_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cnp.2017.07.002","article-title":"A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017","volume":"2","author":"Kane","year":"2017","journal-title":"Clin Neurophysiol Pract"},{"issue":"Suppl. 5","key":"10.1016\/j.yebeh.2019.02.020_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1528-1167.2009.02117.x","article-title":"The autosomal recessively inherited progressive myoclonus epilepsies and their genes","volume":"50","author":"Ramachandran","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.02.020_bb0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-0035-1552620","article-title":"Progressive myoclonus epilepsies","volume":"35","author":"Kalviainen","year":"2015","journal-title":"Semin Neurol"},{"issue":"37","key":"10.1016\/j.yebeh.2019.02.020_bb0085","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.2174\/1381612823666170809114654","article-title":"Update on pharmacological treatment of progressive myoclonus epilepsies","volume":"23","author":"Ferlazzo","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.yebeh.2019.02.020_bb0090","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"14","key":"10.1016\/j.yebeh.2019.02.020_bb0095","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/WNL.0b013e31821435bd","article-title":"Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease)","volume":"76","author":"\u00d8stergaard","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2019.02.020_bb0100","first-page":"45","article-title":"Carbamazepine-induced sinus node dysfunction","volume":"16","author":"Johnson","year":"1997","journal-title":"P R Health Sci J"},{"issue":"6","key":"10.1016\/j.yebeh.2019.02.020_bb0105","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.12108","article-title":"Sinus node dysfunction: an adverse effect of lacosamide","volume":"54","author":"Chinnasami","year":"2013","journal-title":"Epilepsia"},{"issue":"17","key":"10.1016\/j.yebeh.2019.02.020_bb0110","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1089\/neu.2013.3301","article-title":"Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria","volume":"31","author":"Baguley","year":"2014","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.yebeh.2019.02.020_bb0115","first-page":"73","article-title":"Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights","volume":"6","author":"Ostergaard","year":"2016","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2019.02.020_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.04.003","article-title":"Psychiatric side effects and antiepileptic drugs: observations from prospective audits","volume":"71","author":"Stephen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.02.020_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"issue":"12 Suppl 4","key":"10.1016\/j.yebeh.2019.02.020_bb0130","first-page":"S39","article-title":"Optimizing therapy of seizures in adult patients with psychiatric comorbidity","volume":"67","author":"Brodtkorb","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2019.02.020_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018310126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018310126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:26:05Z","timestamp":1761503165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018310126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"alternative-id":["S1525505018310126"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.020","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}